Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 105

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 105
---
 success will depend, in large part, on our ability to anticipate and effectively manage these and other risks associated with our international operations. Any of these risks could harm our international operations and negatively impact our sales, adversely affecting our business, results of operations, financial condition and growth prospects. If we do not successfully leverage the talent available in Argentina and successfully self -fund all research and development initiatives we have in the country, we may incur additional overall costs. We currently rely heavily on our wet -lablaboratory in Argentina (“Argentine Wet -Lab”), where we currently maintain our headquarters as well as perform our main research and development operations. Our operations are based in Argentina and substantially all our sales are made in Argentina. We intend to centralize our research and development activities in Argentina, as part of a phased strategy aligned with the establishment of our processing hub in Mexico. This hub is anticipated to be operational within one year following the Closing. Subsequently, we will centralize our R&D activities in Argentina to enhance regional operational efficiency. Given our centralized research and development structure, it is strategically important that our Argentine Wet -Labactivities, particularly those related to research and development, achieve self -sufficiencyby being funded through revenues generated in Argentina. Our goal is for the Argentine Wet -Labto become self -sustainingby the end of 2025, supported by anticipated growth in revenue from Argentina, where we are working closely with our shareholder and commercial partner in Argentina, CIBIC, to expand in line with the growing demand for local genomics services. However, until we achieve the necessary revenue levels in Argentina, our operations will continue to require external funding sources, and there is no guarantee that revenues in Argentina will meet our self -fundingobjectives within our projected timelines. Additionally, if we are unsuccessful in leveraging the scientific and genetics talent available in Argentina or in aligning our operations to the growth of the local genomics industry, we may face additional costs or funding needs. This reliance on future revenues to support our research and development could affect our business, results of operations, financial condition, and growth prospects. If new regulations emerge regarding telemedicine services, biological sample logistics, or data transfer, we may incur additional compliance costs or face operational disruptions. One of our key differentiators will be the ability to provide telemedicine services and manage biological sample logistics for the Latin American market. While we aim to integrate AI Agents into our telemedicine offerings to enhance scalability, we plan to complement this approach with medical geneticists and other specialists when